Regeneron Reports Phase 2 Data for Guselkumab in Juvenile idiopathic arthritis

Regeneron today announced Phase 2 results for Guselkumab in patients with Juvenile idiopathic arthritis. The study demonstrated that Guselkumab demonstrates durable complete remissions compared to standard of care or placebo. These results provide important insights into the treatment of Juvenile idiopathic arthritis and support the continued development of Guselkumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Guselkumab was consistent with previous observations, with no new safety signals identified.